Ceapro Inc V.CZO

Alternate Symbol(s): CRPOF

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > IntelGenx Results for Comparison

<< Previous

Bullboard Posts

Next >>

Comment by stockfyon Aug 11, 2021 6:35am

46 Views

Post# 33683578

RE:IntelGenx Results for Comparison

Compare now the Enterprise Values for IGXT and CZO. It's obvious that CZO is dirt cheap.

IGXT's Enterprise Value currently is about $60 million (including its cash and the latest debt=notes) while CZO's Enterprise Value (including its cash and zero debt) currently is only $45 million.

archeo753 wrote:
2021 Second Quarter Financial Summary:

Revenue was $162,000, compared to $42,000 in the 2020 second quarter.

Net comprehensive loss was $2.5 million, compared to $1.3 million in Q2-2020.

Adjusted EBITDA loss was $1.7 million, compared to $1.5 million in the 2020 second quarter.

Remember they make oral thin films. Market Cap $89 million.

Ceapro Latest Financials:

Financial Highlights for the First Quarter Ended March 31, 2021

Total sales of $4,702,000 for the first quarter of 2021 compared to $4,273,000 for the comparative period in 2020; an increase of 10% over last year. Beta glucan sales volumes increased by 318% for Q1 2021 vs Q1 2020. With sales being made in US dollars, the decreased exchange rate $US/CDN as compared to the prior period negatively impacted 2021 sales by approximately $364,000.

Net profit of $515,000 for the first quarter of 2021 compared to a net profit of 1,126,000 for the comparative period in 2020.

Research and Development of $817,000 in Q1 2021 vs. $502,000 in 2020. This increased investment was partly due to an accelerated pace for the recruitment of patients for the beta glucan trial as a cholesterol reducer.

Cash generated from operations of $305,000 in Q1 2021 vs. $531,000 in Q1 2020.

Positive working capital balance of $8,246,972 as of March 31, 2021.

Profitable base business, oral thin films and many more products in development.
$48 million market cap.

I am hopefull CZO will eclipse IGX and also companies like BU once positive BG pill results or any other products are ready for sale. Also, $5 million sales for the most recent quarter would be nice.